OSR Holdings, Inc. (OSRH)
| Market Cap | 18.90M -29.0% |
| Revenue (ttm) | 2.91M -17.7% |
| Net Income | -18.01M |
| EPS | -0.92 |
| Shares Out | 33.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,785,783 |
| Open | 0.6428 |
| Previous Close | 0.6911 |
| Day's Range | 0.5500 - 0.6678 |
| 52-Week Range | 0.3803 - 1.7900 |
| Beta | 0.87 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 22, 2026 |
About OSRH
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Germany, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) bio... [Read more]
Financial Performance
In 2025, OSR Holdings's revenue was $2.91 million, a decrease of -17.69% compared to the previous year's $3.53 million. Losses were -$18.01 million, 74.4% more than in 2024.
Financial StatementsNews
Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target
NEW YORK, NY / ACCESS Newswire / May 5, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target o...
OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026
OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 BELLEVUE, WA / ACCESS Newswire / April 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare hold...
OSR Holdings enters $815M global license agreement for VXM01 with BCM Europe
OSR Holdings (OSRH) entered into a definitive global exclusive license agreement with BCM Europe for the development, commercialization, and potential sublicensing of VXM01, its Phase 3-ready oral imm...
OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe
Largest shareholder pledges entire equity stake as collateral for milestone obligations, reinforcing alignment with public shareholders BELLEVUE, WA / ACCESS Newswire / April 29, 2026 / OSR Holdings, ...
OSR Holdings eliminates $2.02M warrant overhang
OSR Holdings (OSRH) announced a strategic transaction for capital structure optimization with White Lion GBM Innovation Fund, centered on the retirement of approximately $2.02M of warrant overhang. As...
OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note
BELLEVUE, WA / ACCESS Newswire / April 9, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings" or the "Company") today announced a strategic transaction for capital structure optimization with Whit...
OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026
BELLEVUE, WA / ACCESS Newswire / March 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing biomedical innovations to improve health and wellness worldwide, today...
Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
NEW YORK CITY, NY / ACCESS Newswire / March 27, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price ...
OSR Holdings announces update to $815M VXM01 licensing deal structure
OSR Holdings (OSRH) announced an updated structure of its previously disclosed binding term sheet dated January 13, 2026 with BCM Europe AG for the global licensing of its lead oncology
OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level
BELLEVUE, WA / ACCESS Newswire / March 23, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced an updated structure of its previously disclosed binding term sheet dated January 13, 2026 with BCM E...
OSR Holdings subsidiary signs NDA with Sinopharm
OSR Holdings (OSRH)subsidiary Woori IO has entered into a mutual non-disclosure agreement, or NDA, with the Beijing-based unit of Sinopharm Group and major state-owned healthcare and pharmaceutical di...
OSR Holdings subsidiary signs NDA with Sinopharm
OSR Holdings (OSRH)subsidiary Woori IO has entered into a mutual non-disclosure agreement, or NDA, with the Beijing-based unit of Sinopharm Group and major state-owned healthcare and pharmaceutical di...
Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities
BELLEVUE, WA / ACCESS Newswire / March 19, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary,...
OSR Holdings granted 180-day Nasdaq extension
OSR Holdings (OSRH) received written notification from The Nasdaq Stock Market LLC granting the Company an additional 180-calendar-day extension to regain compliance with Nasdaq Listing Rule 5550(a)(2...
OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum
BELLEVUE, WASHINGTON / ACCESS Newswire / March 5, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing innovative biomedical technologies, today announced that it has...
OSR Holdings CEO says fundamentals of business ‘remain strong’
In a letter to shareholders, CEO Kuk Hyoun Hwang said, in part, “As the compliance deadline under the minimum bid requirement of NASDAQ approaches, we recognize that market volatility and
CEO Statement to Shareholders
BELLEVUE, WASHINGTON / ACCESS Newswire / February 2, 2026 / Reaffirming Strategic Execution and Long-Term Value Creation As the compliance deadline under the minimum bid requirement of NASDAQ approach...
OSR Holdings completes Woori IO acquisition
OSR Holdings (OSRH) announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignment by Woori IO’s historical shareholders, and the initiation of a strate...
OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries
BELLEVUE, WA / ACCESS Newswire / January 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignmen...
Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch
BELLEVUE, Wash., Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration...
Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform
BELLEVUE, Wash., Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien Wieck...
Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones
BELLVUE, Wash., Jan. 12, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced that its Swiss biotechnology subsidiary, Vaximm AG, has received a binding term sheet from BCM Europe AG...
OSR Holdings announces Woori IO shareholders approve share exchange
OSR Holdings (OSRH) announced that the shareholders of Woori IO approved a share exchange at an Extraordinary General Meeting held at Woori IO’s headquarters in Jeonju, Korea. The approved share
Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings
Company advancing dual clinical pathways, including a Samsung-supported PoC trial in Korea and a planned U.S. FDA trial with a leading California research university BELLEVUE, Wash. , Dec. 19, 2025 /P...
Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement
New York, New York--(Newsfile Corp. - December 4, 2025) - Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (NASDAQ: OSRH), reaffirming its Buy-Emerging rating and 12-month pr...